Evidence map›Paper›PMID 37989820›Full record

ArticleJournal of general internal medicine2024

Decreased Anogenital Gonorrhea and Chlamydia in Transgender and Gender Diverse Primary Care Patients Receiving Gender-Affirming Hormone Therapy.

Sari L Reisner, Madeline B Deutsch, Kenneth H Mayer, David R Pletta, Juwan Campbell, Jennifer Potter, Alex S Keuroghlian, Jaclyn M W Hughto, Andrew Asquith, Dana J Pardee and 5 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of general internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Sari L ReisnerBrigham and Women's Hospital, 221 Longwood Ave, Boston, MA, USA. sreisner@bwh.harvard.edu.
Madeline B DeutschUniversity of California San Francisco, San Francisco, CA, USA.
Kenneth H MayerHarvard Medical School, Boston, MA, USA.
David R PlettaHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Juwan CampbellThe Fenway Institute, Fenway Health, Boston, MA, USA.
Jennifer PotterHarvard Medical School, Boston, MA, USA.
Alex S KeuroghlianHarvard Medical School, Boston, MA, USA.
Jaclyn M W HughtoThe Fenway Institute, Fenway Health, Boston, MA, USA.
Andrew AsquithThe Fenway Institute, Fenway Health, Boston, MA, USA.
Dana J PardeeThe Fenway Institute, Fenway Health, Boston, MA, USA.
Alexander HarrisCallen-Lorde Community Health Center, New York, NY, USA.
Meg QuintBrigham and Women's Hospital, 221 Longwood Ave, Boston, MA, USA.
Chris GrassoThe Fenway Institute, Fenway Health, Boston, MA, USA.
Alex GonzalezHarvard Medical School, Boston, MA, USA.
Asa RadixCallen-Lorde Community Health Center, New York, NY, USA.
Fenway Health · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USCommunity Health Center · USHarvard University · USBrown University · USUniversity of California, San Francisco · US

Funding

NIMHD NIH HHS L60 MD012898
6 · The paper itself

Abstract

backgroundTransgender and gender diverse (TGD) adults in the U.S. experience health disparities, including in anogenital sexually transmitted infections (STI). Gender-affirming hormone therapy (GAHT) is known to be medically necessary and improve health. Few studies have assessed the effect of GAHT on STI diagnoses.

objectiveTo evaluate the effect of GAHT delivered in primary care as an intervention to improve STI outcomes for TGD adults.

designLEGACY is a longitudinal, multisite cohort study of adult TGD primary care patients from two federally qualified community health centers in Boston, MA, and New York, NY.

participantsElectronic health record data for eligible adult TGD patients contributed to the LEGACY research data warehouse (RDW). A total of 6330 LEGACY RDW patients were followed from 2016 to 2019, with 2555 patients providing STI testing data. MAIN MEASURES: GAHT exposure was being prescribed hormones, and the clinical outcome was anogenital gonorrhea or chlamydia diagnoses. Log-Poisson generalized estimating equations assessed the effect of prescription GAHT on primary outcomes, adjusting for age, race, ethnicity, gender identity, poverty level, health insurance, clinical site, and cohort years. KEY

resultsThe median age was 28 years (IQR = 13); the racial breakdown was 20.4% Black, 8.1% Multiracial, 6.9% Asian/Pacific Islander, 1.8% Other; 62.8% White; 21.3% Hispanic/Latinx; 47.0% were assigned female at birth, and 16.0% identified as nonbinary. 86.3% were prescribed hormones. Among those tested, the percentage of patients with a positive anogenital STI diagnosis ranged annually from 10.0 to 12.5% between 2016 and 2019. GAHT prescription was associated with a significant reduction in the risk of anogenital STI diagnosis (aRR = 0.75; 95% CI = 0.59-0.96) over follow-up.

conclusionsGAHT delivered in primary care was associated with less STI morbidity in this TGD cohort over follow-up. Patients may benefit from individualized and tailored clinical care alongside GAHT to optimize STI outcomes.

Indexed as

Chlamydia InfectionsGonorrheaPrimary Health CareTransgender PersonsAdultCohort StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedYoung Adultsexually transmitted infectionstransgender.

Identifiers

PMID37989820
PMCPMC11116345
OpenAlexW4388857574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.